Scarica l'app Stockscreener
1.78
5.33%
0.09
Dopo l'orario di chiusura:
1.77
-0.01
-0.56%
Palisade Bio Inc Borsa (PALI) Ultime notizie
Palisade Bio (PALI) director Jordan Michael Zwick files baseline Form 3 - Stock Titan
Palisade Bio (PALI) director gets 592,300 RSU grant and 20,200 RSUs vest - Stock Titan
Palisade Bio (PALI) director reports major RSU grant and new share holdings - Stock Titan
Palisade Bio (PALI) director Emil Chuang reports new RSU awards - Stock Titan
Palisade Bio (PALI) Holds Steady Near Key Support After Modest GainTriple Top - The League of Women Voters of Texas
Palisade Bio, Inc. Approves Amendments to Equity Incentive and Employee Stock Purchase Plans at 2026 Annual Meeting – Minichart - Minichart
Palisade Bio Shareholders Approve Charter Amendments, Governance Matters - TipRanks
Palisade Bio (PALI) raises authorized shares to 450M and refreshes equity plans - Stock Titan
Palisade Bio adds two directors with biotech expertise - Investing.com
Palisade Bio adds two directors with biotech expertise By Investing.com - Investing.com Canada
Palisade Bio Continues to Build on PALI-2108 Clinical Progress as It Advances Toward Phase 2 Development >PALI - Moomoo
Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors - GlobeNewswire
PALI Q1 2026 Earnings: Net Loss Wider Than Estimates as Pre-Revenue Biotech Advances PipelineSpecial Dividend Alert - newsline.com
Palisade Bio, Inc. to Present on PDE4 Inhibitor Prodrug Approach for Fibrostenotic Crohn's Disease at NYAS Symposium - Quiver Quantitative
Experimental pill targets fibrostenotic Crohn’s, a form with no approved drugs - Stock Titan
B. Riley Securities Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Palisade Bio (PALI) Gets a Buy from B. Riley Securities - The Globe and Mail
PALI Technical Analysis | Trend, Signals & Chart Patterns | PALISADE BIO INC (NASDAQ:PALI) - ChartMill
PALI Q1 2026 Earnings: Deeper Loss Than Expected as Pre-Revenue Biotech Faces Market SkepticismProfit Cycle Analysis - newsline.com
[SCHEDULE 13G] PALISADE BIO, INC. Passive Investment Disclosure (>5%) - Stock Titan
Palisade Bio to present at Jefferies Healthcare... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Palisade Bio to Participate in the Jefferies Global Healthcare Conference - Weekly Voice
Palisade Bio to present once-daily PDE4 prodrugs at NYC event - Stock Titan
Verra Mobility, Zscaler, Box And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Palisade Bio Inc. (PALI) Edges Higher on Modest Volume, Testing Resistance LevelsPassive Flow - The Legal Advocate
Palisade Bio (PALI) Edges Higher as Shares Test Key Resistance ZoneFund Manager Survey - newsline.com
PALI Q1 2026 Earnings: EPS Misses Estimates as Palisade Bio Advances Pipeline EffortsGuidance Downgrade Alert - Newser
PALI Should I Buy - Intellectia AI
[EFFECT] PALISADE BIO, INC. SEC Filing - Stock Titan
Palisade Bio, Inc.Common Stock (NQ: PALI - FinancialContent
Palisade Bio Records Q1 Earnings and Advances Clinical Pipeline - HarianBasis.co
Palisade Bio (PALI) Reports Q1 2026 Results as R&D Expenses Rise to $6.4M - Insider Monkey
Number of shareholders of Palisade Bio, Inc. – MUN:7NS0 - TradingView
10 Best NASDAQ Stocks Under $5 to Buy Right Now - Insider Monkey
RA Capital and partners disclose 9.99% stake in Palisade Bio (PALI) via warrants and shares - Stock Titan
[SCHEDULE 13G/A] PALISADE BIO, INC. Amended Passive Investment Disclosure - Stock Titan
Commodore Capital reports 12.37M-share stake in Palisade Bio (PALI) - Stock Titan
Perceptive Advisors (NASDAQ: PALI) reports a 7.9% collective stake in Palisade Bio - Stock Titan
Ameriprise/Columbia disclose 8.71M-share stake in Palisade Bio (NASDAQ: PALI) - Stock Titan
We're Not Worried About Palisade Bio's (NASDAQ:PALI) Cash Burn - Yahoo Finance
Analysts Are Bullish on These Healthcare Stocks: BridgeBio Pharma (BBIO), Palisade Bio (PALI) - The Globe and Mail
Palisade Bio Incmay offer and sell up to $300 million of securitiesSEC filing - marketscreener.com
Palisade Bio (NASDAQ: PALI) files $300M shelf to offer securities - Stock Titan
Palisade Bio Q1 net loss widens on higher R&D costs - TradingView
Palisade Bio (PALI) ramps PALI-2108 trials with $132.6M cash runway - Stock Titan
BRIEF-Palisade Bio Q1 EPS USD -0.05 - TradingView
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108 - GlobeNewswire
Palisade Bio (NASDAQ: PALI) boosts R&D spend to advance PALI-2108 - Stock Titan
Palisade Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
TradingKey - TradingKey
Palisade Bio Inc expected to post a loss of 4 cents a shareEarnings Preview - TradingView
Palisade Bio (PALI) price target decreased by 12.09% to 10.20 - MSN
Palisade Bio, Inc. (NASDAQ:PALI) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Palisade Bio Data Supports Once-Daily Ulcerative Colitis Treatment Due to Sustained IC90 Coverage - geneonline.com
Palisade Bio presents pharmacokinetic data for ulcerative colitis drug By Investing.com - Investing.com South Africa
Palisade Bio presents pharmacokinetic data for ulcerative colitis drug - Investing.com
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):